X4 Pharma gains as immune disease drug meets main goal in late-stage study

X4 Pharmaceuticals

16/05/2023 22:04

** Drug developer X4 Pharmaceuticals Inc's  XFOR.O  shares
rise ~4% to $1.83 after market
    ** Company says its experimental drug to treat a rare
genetic immunodeficiency disease significantly reduced infection
rate vs placebo  urn:newsml:reuters.com:*:nGNX6N3x6F
    ** The drug candidate, mavorixafor, is being developed to
treat WHIM syndrome, which makes affected individuals more
susceptible to potentially life-threatening bacterial infections
    ** The drug showed 60% reduction in infection rate and
showed over 75% reduction in the percentage of individuals
experiencing severe infections vs placebo - XFOR
    ** Company plans to submit marketing application to the U.S.
health regulator early in H2 2023 
    ** As of last close, stock up ~77% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com))